Daewoong’s patent trial for ezetimibe while the patent is expiring in 2 months
Daewoong Pharmaceutical has attracted attention as filing a patent lawsuit for ‘ezetimibe,’ a substance for the MSD’s hyperlipidemia treatment, which will be expired in 2 months.
Ezetimibe is a substance contained in the MSD’s complex drugs, Atozet and Vytorin. Atozet is a complex hyperlipidemia...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
